Paul KotronisSenior Vice President, Commercial Real Estate, Peapack PrivateBEDMINSTER, N.J., July 10, 2026 (GLOBE NEWSWIRE) — Peapack-Gladstone Financial Corporation (NASDAQ Global Select Market: PGC) and Peapack Private Bank & Trust are pleased to announce the appointment of Paul Kotronis as Senior Managing Director, Commercial Real Estate. In this role, Kotronis will support and expand the Bank’s Commercial Real estate lending platform, drive relationship-based deposit growth, and further strengthen Peapack Private’s presence in the New York and New Jersey markets.   “Paul’s extensive commercial real estate lending experience, deep market relationships, and proven leadership make him an exceptional addition to our team,” said Joseph Fingerman, Senior Managing Director and President of Commercial Real...

RUSTON, La., July 10, 2026 (GLOBE NEWSWIRE) — Origin Bancorp, Inc. (NYSE: OBK) (“Origin”), the financial holding company for Origin Bank, plans to issue second quarter 2026 results after the market closes on Wednesday, July 22, 2026, and hold a conference call to discuss such results on Thursday, July 23, 2026, at 8:00 a.m. Central Time (9:00 a.m. Eastern Time). The conference call will be hosted by Drake Mills, Chairman, President and CEO of Origin, William J. Wallace, IV, Chief Financial Officer of Origin, and Lance Hall, President and CEO of Origin Bank. Conference Call and Live Webcast        To participate in the live conference call, please dial +1 (929) 272-1574 (U.S. Local / International 1); +1 (857) 999-3259 (U.S. Local / International 2); +1 (888) 700-7550 (U.S. Toll Free), enter Conference ID: 75275 and request to be...

Reporting of transactions made by persons discharging managerial responsibilities and their closely associated persons in InstallatørGruppen’s shares Pursuant to the Market Abuse Regulation (EU) no. 596/2014, as amended, article 19, InstallatørGruppen A/S (“InstallatørGruppen”) hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities in InstallatørGruppen and their closely associated persons in InstallatørGruppen’s shares. Reference is made to company announcement no. 14 – 2026 dated 10 July 2026 related to the end of the stabilisation period in connection with the initial public offering (the “Offering”) and admission to trading of the shares of InstallatørGruppen, and company announcement no. 15 – 2026 dated 10 July 2026 related to the partial exercise of the overallotment...

BEIJING, July 10, 2026 (GLOBE NEWSWIRE) — Haoxi Health Technology Ltd (NASDAQ: HAO) (“Haoxi” or the “Company”), today announced that it has entered into a definitive agreement with certain investors for the purchase and sale of an aggregate of 10,000,000 of the Company’s Class A Ordinary Shares, par value $0.32 per share (the “Shares”) (or pre-funded warrants in lieu thereof) at a purchase price of $0.40 per share in a registered direct offering. The purchase price for the pre-funded warrants is identical to the purchase price for Shares, less the exercise price of $0.33 per share. The aggregate gross proceeds to the Company of this offering are expected to be approximately $4 million. The transaction is expected to close on or about July 13, 2026, subject to the satisfaction of customary closing conditions. Univest Securities,...

Mountain View Estates will offer 10 expansive home sites and exceptional home designs in a sought-after Southern California location THOUSAND OAKS, Calif., July 10, 2026 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, today announced its newest community, Mountain View Estates, is coming soon to Thousand Oaks, California. This exclusive enclave of just 10 expansive home sites is anticipated to open for sale in early 2027. Mountain View Estates will provide home shoppers with a rare opportunity to own a luxury home in one of Southern California’s most desirable locations. These striking two-story homes will offer over 3,600 square feet of living space, featuring bright, open-concept gathering areas, 5 bedrooms, 5.5 bathrooms, and 2- to 3-car garages. Detached casita options will also...

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL This announcement does not constitute an offering circular, or a prospectus as defined by Regulation (EU) No. 2017/1129 of 14 June 2017, as amended (the “Prospectus Regulation”) and nothing herein shall be construed as an offering of securities. The offer to acquire securities pursuant to the offering of shares in InstallatørGruppen A/S (“InstallatørGruppen” or the “Company”) will be made, and any investment decision by an investor should be made, solely on the basis of information that is contained in the offering circular or prospectus, which is made generally available in Denmark in connection with the...

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL This announcement does not constitute an offering circular, or a prospectus as defined by Regulation (EU) No. 2017/1129 of 14 June 2017, as amended (the “Prospectus Regulation”) and nothing herein shall be construed as an offering of securities. The offer to acquire securities pursuant to the offering of shares in InstallatørGruppen A/S (“InstallatørGruppen” or the “Company”) will be made, and any investment decision by an investor should be made, solely on the basis of information that is contained in the offering circular or prospectus, which is made generally available in Denmark in connection with the...

PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON ITS CLINICAL PROGRAM, SUSPENDING SOME NON-PRIORITY CLINICAL TRIALS TO FOCUS ON TWO CLINICAL PROGRAMS Paris, July 10, 2026, 6pm CET AB Science SA (Euronext – FR0010557264 – AB) today provides an update on its clinical development program and announces the discontinuation of certain non-priority clinical studies in order to focus on two clinical programs, the AB8939 program for acute myeloid leukemia and the masitinib program for amyotrophic lateral sclerosis. Following the company’s press release dated April 16 [1], three clinical studies—which the company currently considers non-priority and for which patient enrollment had been suspended—are being discontinued, namely:Phase 2 study (AB20006) of masitinib in mast cell activation syndrome Phase 3 study (AB15003) of masitinib in...